The cost-effectiveness and cost-utility of statin drug for the treatment of patients with cardiovascular disease, a systematic review
| Autor: | Aziz Rezapour, Mahmoud Eisavi, Elaheh Mazaheri, Marziye Hadian, Sajad Vahedi, Abdosaleh Jafari |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Statin Cost–benefit analysis statin drugs Cost effectiveness medicine.drug_class business.industry Atorvastatin Cost-benefit analysis Public Health Environmental and Occupational Health Psychological intervention Review Article Disease cardiovascular diseases systematic review Economic evaluation medicine Medicine Rosuvastatin Intensive care medicine business medicine.drug |
| Zdroj: | International Journal of Preventive Medicine International Journal of Preventive Medicine, Vol 12, Iss 1, Pp 39-39 (2021) |
| ISSN: | 2008-7802 |
| DOI: | 10.4103/ijpvm.ijpvm_125_20 |
| Popis: | Cardiovascular diseases impose a burden of disease and economic burden on society. With regard to different drugs are used to treat cardiovascular disease; these interventions should be economically evaluated and them that the most cost-effective were selected. The aim of this study was to investigate the studies carried on the cost-effectiveness and cost-utility of statin drugs for the treatment of patients with cardiovascular disease between 2004 and 2020. Quality assessment of the articles was examined by Drummond's checklist. Given that the inclusion criteria, 26 articles included in the review. The results of this review showed that many articles related to the economic evaluation of statin drugs adhered international standards for performing economic evaluation studies. All the studies mentioned the source of effectiveness (the second criteria) and alternative options for the comparison (the third criteria). Atorvastatin and rosuvastatin drugs were the main options for the comparison in the studies. Although the results of the studies were different in some aspects, such as the type of modeling, costs items and the study perspective, they reached the same results which the use of statin drugs versus no-drug can decrease cost, cardiovascular events and deaths and increase QALY. The results were nearly different due to study design, time horizon, efficacy, and drug prices. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|